Sensus Healthcare Inc. (NASDAQ: SRTS) stock jumped 30.73% on Friday to $14.55 against a previous-day closing price of $11.13. With 2.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.2 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $14.80 whereas the lowest price it dropped to was $12.03. The 52-week range on SRTS shows that it touched its highest point at $11.96 and its lowest point at $3.21 during that stretch. It currently has a 1-year price target of $16.50. Beta for the stock currently stands at 0.81.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SRTS was up-trending over the past week, with a rise of 29.22%, but this was up by 66.10% over a month. Three-month performance surged to 103.21% while six-month performance rose 76.36%. The stock gained 311.02% in the past year, while it has gained 101.52% so far this year. A look at the trailing 12-month EPS for SRTS yields 1.28 with Next year EPS estimates of 0.87. For the next quarter, that number is 0.11. This implies an EPS growth rate of 160.00% for this year and -41.25% for next year.
Float and Shares Shorts:
At present, 16.50 million SRTS shares are outstanding with a float of 12.84 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.4 million, which was 2.37% higher than short shares on Jun 14, 2022. In addition to Mr. Joseph C. Sardano as the firm’s Co-Founder, Chairman & CEO, Mr. Michael J. Sardano serves as its Pres & Gen. Counsel.
Through their ownership of 26.66% of SRTS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.62% of SRTS, in contrast to 29.51% held by mutual funds. Shares owned by individuals account for 19.74%. As the largest shareholder in SRTS with 3.59% of the stake, Hillsdale Investment Management, holds 599,436 shares worth 599,436. A second-largest stockholder of SRTS, The Vanguard Group, Inc., holds 588,910 shares, controlling over 3.53% of the firm’s shares. Acadian Asset Management LLC is the third largest shareholder in SRTS, holding 326,262 shares or 1.96% stake. With a 2.31% stake in SRTS, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 385,579 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.10% of SRTS stock, is the second-largest Mutual Fund holder. It holds 184,192 shares valued at 1.41 million. SEI Global Master Fund Plc – US S holds 0.56% of the stake in SRTS, owning 93,204 shares worth 0.72 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SRTS since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SRTS analysts setting a high price target of $20.00 and a low target of $14.00, the average target price over the next 12 months is $16.50. Based on these targets, SRTS could surge 37.46% to reach the target high and fall by -3.78% to reach the target low. Reaching the average price target will result in a growth of 13.4% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SRTS will report FY 2022 earnings on 02/02/2023. Analysts have provided yearly estimates in a range of $1.64 being high and $0.81 being low. For SRTS, this leads to a yearly average estimate of $1.40. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sensus Healthcare Inc. surprised analysts by $0.08 when it reported $0.21 EPS against a consensus estimate of $0.13. The surprise factor in the prior quarter was $0.93. Based on analyst estimates, the high estimate for the next quarter is $0.19 and the low estimate is $0.05. The average estimate for the next quarter is thus $0.13.
Summary of Insider Activity:
Insiders traded SRTS stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 10,000 shares were sold. The number of buy transactions has increased to 2 while that of sell transactions has risen to 26 over the past year. The total number of shares bought during that period was 19,000 while 387,490 shares were sold.